Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing

Gene Therapy volume 24, pages 503–505 (2017)Cite this article

Subjects

Abstract

An experimental approach for gene therapy of spinomuscular atrophy has been reported to prevent development of the neuromuscular features of this lethal and previously untreatable disorder. The approach involves treatment of patients suffering from SMN1-associated infantile form of the disease with a splice-switching antisense oligonucleotide (ASO) that corrects aberrant splicing of the nearly identical SMN2 gene to allow the generation of functional SMN protein, thereby mitigating the development of the disease. This technique represents the first apparently effective therapy for spinal muscular atrophy (SMA) and an important documentation for ASO technology for therapy of neurodegenerative disease. These results with one form of SMA are likely to be relevant for similar applications to other SMA types and are likely to inspire application to a number of other intractable neurodegenerative diseases such as Huntington’s disease, amyotrophic lateral sclerosis and possibly even the extremely common Parkinson’s and Alzheimer’s diseases and others. Nevertheless, the scientific and medical importance of this advance is marred by a pricing policy by the corporate sponsors that may complicate accessibility of the drug for some desperate patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Beltrão-Braga PC, Pignatari GC, Russo FB, Fernandes IR, Muotri AR . In-a-dish: induced pluripotent stem cells as a novel model for human diseases. Cytometry A 2013; 83: 11–17.

    Article  Google Scholar 

  2. Naldini L . Gene therapy returns to centre stage. Nature 2015; 526: 351–360.

    Article  CAS  Google Scholar 

  3. Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C et al. Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 2016; 388: 476–487.

    Article  CAS  Google Scholar 

  4. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013; 341: 1233158.

    Article  Google Scholar 

  5. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 2016; 388: 3017–3026.

    Article  CAS  Google Scholar 

  6. Bishop KM . Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases. Neuropharmacology 2017; 120: 56–62.

    Article  CAS  Google Scholar 

  7. Sridharan K, Gogtay NJ . Therapeutic nucleic acids: current clinical status. Br J Clin Pharmacol. 2016; 82: 659–672.

    Article  Google Scholar 

  8. Lundin KE, Gissberg O, Smith CI . Oligonucleotide therapies: the past and the present. Hum Gene Ther 2015; 26: 475–485.

    Article  CAS  Google Scholar 

  9. Arnold WD, Kassar D, Kissel JT . Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve 2015; 51: 157–167.

    Article  CAS  Google Scholar 

  10. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett CF et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010; 24: 1634–1644.

    Article  CAS  Google Scholar 

  11. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR . Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 2008; 82: 834–848.

    Article  CAS  Google Scholar 

  12. Passini MA, Bu J, Richards AM, Sardi SP, O'Riordan CR, Klinger KW et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 2011; 3: 72ra18.

    Article  Google Scholar 

  13. Singh NK, Singh NN, Androphy EJ, Singh RN . Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 2006; 26: 1333–1346.

    Article  CAS  Google Scholar 

  14. Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116: 2290–2296.

    Article  CAS  Google Scholar 

  15. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF et al. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 2011; 478: 123–126.

    Article  CAS  Google Scholar 

  16. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012; 74: 1031–1044.

    Article  CAS  Google Scholar 

  17. Zaghloul E, Gissberg O, Moreno P, Siggens L, Mattias H, Jørgensen A et al. CTG repeat-targeting oligonucleotides for down-regulating Huntingtin expression. Nucleic Acids Res 2017; 45: 5153–5169.

    Article  CAS  Google Scholar 

  18. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose escalation study. Lancet 2016; 388: 3017–3026.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UCSD School of Medicine, University of California-San Diego, La Jolla, CA, USA

    T Friedmann

Authors
  1. T Friedmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Friedmann.

Ethics declarations

Competing interests

The author declares no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Friedmann, T. Gene therapy for spinomuscular atrophy: a biomedical advance, a missed opportunity for more equitable drug pricing. Gene Ther 24, 503–505 (2017). https://doi.org/10.1038/gt.2017.48

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/gt.2017.48

This article is cited by

Search

Advanced search

Quick links